192 results about "Bone forming" patented technology

The invention provides an application of bifidobacterium animalis subsp. Lactis CP-9 in preparation of a product for promoting bone growth and development or improving bone health. Long-term research and a large number of experiments show that the bifidobacterium animalis subsp. Lactis CP-9 can improve the bone volume fraction, the bone trabecula thickness, the bone density and the bone volume of an organism, and can also effectively improve the growth hormone level and the insulin-like growth factor 1 level, so that bone growth and development are promoted. Meanwhile, the bifidobacterium animalis subsp. Lactis CP-9 can effectively improve the N-terminal propeptide level, osteocalcin level, bone morphogenetic protein level and osteoprotectin level of I-type procollagen in a body, and remarkably reduce the amino-terminal peptide level of the I-type collagen and the ligand level of nuclear factor kappa B receptor activating factor, so that osteoblast differentiation is promoted, osteoclast differentiation is inhibited, and osteoclast differentiation is inhibited. Furthermore, bone formation is promoted, bone resorption is inhibited, bone metabolism is improved, and finally the effect of improving bone health is achieved.

The invention provides a compound with a structure as shown in a formula (I). The compound can be used as a polyphenol organic ligand to be self-assembled with metal ions to form metal polyphenol nanoparticles. The nano-particles have a bone targeting effect, are safe, effective, stable and uniform, can realize whole-body transfer, can be degraded in a bone pathology microenvironment, have regulation and control effects on bone resorption and bone formation, can cooperatively regulate and control bone balance, and have a great application prospect in the field of bone diseases such as osteoporosis. # imgabs0 #

A bone insert includes a cap having a convex top surface, an elongated stem, and a barrier between the cap and the stem. The stem of the bone insert is inserted into a hole formed in a host bone until the barrier is pressed against the exposed bone. The bone implant can be placed against a small focus contact point on the cap. Liquid cement can be injected into a space volume between the host bone and a bone implant. The cap can be made of a material and / or have surface features that create a strong bond with the cement when the liquid cement cures. The stem can be made of a material and / or have bone ingrowth surface features that create a strong bond with the bone.

The invention provides a composition for promoting bone health and bone formation as well as application and a product thereof, and belongs to the field of foods. The composition disclosed by the invention is prepared from the following components in parts by weight: 1 to 5 parts of osteopontin, 1 to 50 parts of 2 '-fucosyllactose and 0.05 to 50 parts of a calcium source. The composition disclosed by the invention shows a relatively good synergistic effect in promoting calcium absorption, and can be used for improving bone density, preventing and treating osteoporosis and the like.

The invention belongs to the field of medicines, and particularly relates to application of a new target NCSTN for regulating and controlling bone metabolism and an agonist of the new target NCSTN in preparation of a medicine for preventing or treating osteoporosis. The invention aims to provide a new target NCSTN for regulating and controlling bone metabolism and application of the new target NCSTN in promoting osteogenic activity, inhibiting osteoclast activity and treating osteoporosis. According to the invention, the mechanism of the NCSTN agonist for treating osteoporosis is found for the first time, and the NCSTN agonist has the effects of inhibiting osteoclast maturation and differentiation and promoting osteoblast bone formation function. The mechanism is greatly different from the previously reported mechanism of singly inhibiting bone resorption or singly promoting bone formation, and the osteoporosis treatment which simultaneously acts on bone resorption and bone formation can greatly reduce the adverse reaction of the body to the medicine.

The invention discloses application of a Chibby1 (CBY1) inhibitor in preparation of an anti-osteoporosis medicine for promoting bone formation, and belongs to the technical field of biological medicines. It is found for the first time that CBY1 can inhibit bone marrow stromal cells from differentiating into osteoblasts, and bone marrow stromal cells with CBY1 gene silencing are increased in osteoblast differentiation. According to the invention, it is proposed for the first time that osteoblast differentiation can be promoted by reducing CBY1 expression or inhibiting the CBY1 function, and the CBY1 inhibitor has the potential of increasing osteogenic activity and preventing and treating osteoporosis by inhibiting CBY1 expression or inhibiting the CBY1 function.

The invention discloses an active bone defect repair material and a preparation method thereof. The bone defect repair material is prepared by compounding collagen extracted from an animal source, a calcined bone matrix and bone morphogenetic protein composite microspheres and molding through a photocuring 3D printing technology. From the perspective of bionics, collagen is used as a framework material, a calcined bone matrix with low immunogenicity is used as a hard material to enhance mechanical support of the material, and bone morphogenetic protein composite microspheres have a synergistic effect, so that undifferentiated mesenchymal stem cells are guided to develop towards a specific direction in a long-acting manner. After the active bone defect repair material is implanted into a bone defect part, a microenvironment beneficial to cell adhesion and proliferation is provided for cells, and meanwhile, bone morphogenetic protein is slowly released and can act on the bone defect part for a long time, so that the differentiation and maturation process of osteoblasts is effectively promoted, and bone repair of the bone defect part is promoted.

The invention discloses a preparation method and application of milk-derived peptide capable of efficiently promoting calcium absorption and bone formation, and relates to the field of dairy product processing. Casein in milk is hydrolyzed through papain or protease of similar enzymolysis sites, a primary product is obtained through concentration, and a final product is obtained through subsequent storage or drying and other technological operations. The obtained hydrolysate has outstanding functions of promoting calcium absorption and bone formation, especially in bone formation.

The invention relates to the technical field of medical preparations, and particularly discloses a selenium-based anti-postmenopausal osteoporosis medicine and a preparation method and application thereof.The selenium-based anti-postmenopausal osteoporosis medicine comprises a main active component, a secondary active component and an auxiliary active component, the main active component is a nano-selenium-phytoestrogen compound and is formed by covalent coupling of selenomethionine and soy isoflavone, the particle size of the main active component is 50-200 nm, and the particle size of the auxiliary active component is 100-200 nm; the mass of the selenium element accounts for 5-30% of the mass of the compound; the auxiliary active component is a collagen peptide-calcium chelate and is prepared from marine collagen peptide and calcium citrate through chelation reaction, and the mass ratio of the calcium element to the collagen peptide is (1: 3)-(1: 5); the targeted delivery carrier is folic acid modified chitosan nanoparticles and is used for loading the main active component and the auxiliary active component; the auxiliary materials comprise a disintegrating agent, a lubricating agent and a pH-sensitive enteric coating material; through the synergistic effect of the main active ingredient nano-selenium-phytoestrogen compound and the auxiliary active ingredient collagen peptide-calcium chelate, bone formation can be promoted and bone resorption can be inhibited at the same time, and dual-function treatment is achieved.

The invention discloses a long-chain non-coding RNA (Ribonucleic Acid) and application thereof in regulating osteogenic differentiation of bone marrow mesenchymal stem cells. It is found that overexpression of long-chain non-coding RNA (lncRNA Gm20628) with the nucleotide sequence shown in SEQ ID NO.1 in bone marrow mesenchymal stem cells can effectively promote osteogenic differentiation of the bone marrow mesenchymal stem cells, and then bone defect repair of a mouse with skull injury is promoted. Therefore, the invention provides application of the expression promoter of the lncRNA Gm20628 in preparation for enhancing bone regeneration, repairing bone defects and treating osteoporosis and bone formation disorder related diseases. The method is not only beneficial to treatment of diseases related to the bone marrow mesenchymal stem cells, but also beneficial to construction of bone organs.

This invention provides aragonite- and calcite-based scaffolds for the repair, regeneration, enhancement of formation or a combination thereof of cartilage and / or bone, which scaffolds comprise at least two phases, wherein each phase differs in terms of its chemical content, or structure, kits comprising the same, processes for producing solid aragonite or calcite scaffolds and methods of use thereof.

The invention relates to the technical field of biology, in particular to application of a GGPS1 activator, a pharmaceutical composition, a kit and a method. The invention relates to bone metabolism regulation and bone regeneration. It is found that improvement of GGPS1 expression / activity can activate TGF-beta / Smad2 / 3 by down-regulating LTBP1, so that human bone marrow mesenchymal stem cells are converted from adipogenesis to osteogenesis, and bone formation and bone defect repair are promoted. The invention provides a drug containing a GGPS1 activator and a controlled release composition for implantation, which are used for osteoporosis, bone mass reduction, delayed fracture healing and the like. The invention also provides an in-vitro screening and evaluation method and a detection kit, and the indexes such as p-Smad2 / 3, alizarin red, oil red O and the like are used for judgment. The invention realizes upstream heavy balance and has the advantages of bone promotion and fat suppression.

To highly accurately predict effects of a drug administered to a subject.SOLUTION: A prediction system includes an acquisition unit and a prediction unit. The acquisition unit acquires subject information including a medical image showing bones of a subject. The prediction unit outputs drug prediction information regarding effects of drugs acting on at least one of bone formation and bone absorption, using a drug effect prediction model for predicting effects of drugs on the basis of input information including the subject information and drug information on drugs.SELECTED DRAWING: Figure 3

The present invention relates to an apparatus (10) configured and adapted to remove the flank bones (11) of a headless, slaughtered, preferably opened abdominal cavity fish (12), wherein the fish is conveyed in a conveying direction T with its tail forward and its spine (13) placed on a conveying saddle (14), the apparatus comprising at least: an upper bone guide (15) configured and adapted to guide the spine (13) from the dorsal side of the fish (12) to be processed; and a lower bone guide (16) configured and adapted to guide the ventral radii (44) of the fish (12) to be processed, the ventral radii being formed in the region from the tail to the abdominal cavity. The invention relates to a separation unit (17) for detaching fillets from the flank bones (11) surrounding the abdominal cavity of the fish (12) to be processed, wherein the separation unit (17) includes a separation mechanism (18) having a corresponding opposing unit (19) and capable of moving from a standby position to a working position and vice versa. The device (10) is characterized in that a detachment device (20) is located within the area of ​​the upper bone guide (15) and is configured and adapted to at least loosen the bone connections (21) between the individual flank bones (11) and the vertebrae (13) of at least some of the flank bones (11). The invention also relates to a corresponding slicer (40) having such a device (10) and a corresponding method.

This invention pertains to spinal pedicle screws, specifically locking spinal pedicle screws, including perforated pedicle screws and cortical bone screws that work with them. The proximal end of the self-locking master screw is thickened. A through-hole is provided in the thickened section of the pedicle screw, and the cortical bone screw is driven into the through-hole and fixed to the upper and lower cortical bone layers of the pedicle to form a triangular fixation. After the pedicle screw is implanted, both ends of the through-hole of the pedicle screw are located inside the pedicle. A hole is drilled from the posterolateral aspect of the pedicle using a special aiming device, passing forward and upward through the oblique hole of the pedicle screw, and then through the anterior and superior cortical bone of the pedicle. After measuring the length, a suitable cortical bone screw is selected, screwed in, and locked, fixing the posterolateral cortical bone, the pedicle screw, and the anterior and superior cortical bone of the pedicle. The screw is positioned in a safe area of ​​the superior cortical bone of the pedicle. The cortical bone screw is fixed to the upper and lower cortical bone of the pedicle by passing through the oblique hole, thus locking the position of the pedicle screw.

The invention belongs to the technical field of biology, and particularly relates to a construction method of epigenome edited zebrafish, sgRNA of a targeted zebrafish runx2b gene promoter region and application of the sgRNA. The invention provides a construction method of epigenome edited zebrafish, which comprises the step of carrying out methylation editing by using a CRISPR / dCas9-methyltransferase system targeting runx2b gene promoter region, thereby inhibiting runx2b gene expression and reducing intermuscular bone formation. According to the method, the expression level of the runx2b gene is accurately regulated and controlled through an epigenetic editing technology on the premise that a DNA sequence is not changed, and formation of fish intermuscular bones is effectively reduced. The zebra fish F0 treated by the method represents that the runx2b mRNA expression level is obviously reduced, and the intermuscular bones of the eleventh to sixteenth sarcomedo regions of adult F0 generation fish are obviously shorter than those of a control group, and the shortening range reaches 23.3% to 38.8%. Besides, the method provides theoretical basis and technical support for improving fish economic traits by accurately regulating and controlling the expression mode of the key economic trait gene and simultaneously keeping the integrity of genome DNA (Deoxyribose Nucleic Acid).

Provided herein are methods of treating erosive hand osteoarthritis (OA) in a subject in need thereof, methods of reducing radiographic erosive progression, joint space narrowing, cartilage degradation, and / or bone formation in a subject in need thereof (e.g., a subject suffering from erosive hand OA), methods of inhibiting the development of new erosive joints in a subject in need thereof (e.g., a subject suffering from erosive hand OA), and methods of reducing pain in a subject with erosive hand OA. Also provided herein are uses of denosumab in the manufacture of a medicament adapted for use in a method described herein, as well as pharmaceutical compositions comprising denosumab for use in a method described herein.

The present invention relates to a biosensor that enables the detection of biomarkers related to bone metabolism through saliva samples. This biosensor, which uses a saliva sampling method and offers an economical and user-friendly solution by adopting a non-invasive approach, can detect biomarkers related to bone formation and resorption such as Procollagen Type I N-terminal Propeptide (PINP) and β-C- terminal Telopeptide (β-CTX) in saliva with high sensitivity. The present invention increases patient comfort while also providing rapid analysis, making the diagnosis and treatment processes of diseases related to bone metabolism more efficient.

The present invention addresses the problem of providing an osteogenesis promoting agent and a pharmaceutical composition for preventing or treating a disease or a symptom involving bone defect, osteogenesis imperfecta, osteogenesis disorder, and / or bone hyperresorption.　The problem is solved by: a compound represented by general formula (I), a salt thereof, or a prodrug thereof; and a composition and a pharmaceutical composition containing the same.

The present invention provides compositions and methods for treating a hypophosphatemic disorder, such as X-linked hypophosphatemia (XLH). The method entails administering to a subject a pharmaceutical composition containing an anti-FGF23 ligand, wherein the dosing regimen of the pharmaceutical is designed to reach effective and efficient control of FGF23 activity.

The present invention discloses neutrophils that promote bone formation and angiogenesis, and a preparation method and application thereof. The repair neutrophils are CD45 + Ly6G + CD54 + CD274 + GLUT1 + The cell subpopulation induced by physical electrical stimulation can play a role in promoting tissue repair. In addition, the preparation process of the repair neutrophils of the present invention is simple and easy to operate, which can achieve mass production and clinical promotion and application.

The present invention relates to the field of microorganisms, and in particular to a strain of anaerobic fecal coryneform bacteria CML199, a biological preparation and its application in preparing products for improving the performance of laying hens. The present invention has discovered a new anaerobic fecal coryneform bacteria (Anaerostipes caccae) CML199 without toxic side effects, and its preservation number is CGMCC No.31340. The anaerobic fecal coryneform bacteria can promote the bone development of laying hens, increase the level of bone formation markers in the femur, increase the level of bone formation markers in serum, improve the bone marrow immune microenvironment, and improve the eggshell quality. It is expected to be developed into a new and effective probiotic preparation, and has a very broad application prospect in the laying hen industry.

A polypeptide or a modifier thereof. The polypeptide or the modifier thereof has the effect of promoting bone formation, and can be used for preventing and / or treating bone diseases.

The invention discloses an application of a JAM3 modified engineered vesicle in preparation of a medicine for treating bone injury, the JAM3 modified engineered vesicle is prepared, and the osteogenesis promoting effect of the JAM3 modified engineered vesicle on bone marrow mesenchymal stem cells (BMSCs) is proved through ALP staining, RT-qPCR, WB and other experiments at the cellular level, so that the osteogenesis promoting effect of the JAM3 modified engineered vesicle on the bone marrow mesenchymal stem cells (BMSCs) is improved, and the osteogenesis promoting effect of the JAM3 modified engineered vesicle on the bone marrow mesenchymal stem cells (BMSCs) is improved. Meanwhile, the effect of JAM3 modified engineered vesicles on promoting osteogenesis of bone defect mice is defined through in-vivo experiments. According to the invention, osteogenesis direction differentiation and bone formation capability of BMSC can be promoted, and bone formation capability of bone defect mice can be promoted in vivo; the compound can be used for treating related diseases such as bone injury.

The invention relates to the technical field of biomedicine, in particular to application of osteoblasts derived from jaw tissues in preparation of pre-vascularization bone cell membranes. According to the application, after the magnetic nanoparticles are labeled, cryopreserved bone-derived osteoblasts and vascular endothelial cells are magnetically attracted layer by layer for several times, the pre-vascularized osteoblast cell sheet can be successfully constructed in vitro, and compared with a control group, the VEGF-A and BMP2 protein expression levels of a pre-vascularized treatment group are remarkably increased, so that the pre-vascularized osteoblast cell sheet has a good application prospect. The pre-vascularized bone cell sheet has good ability to promote angiogenesis and bone formation, provides new theoretical guidance for optimizing and constructing pre-vascularized bone tissues, and provides a new method for clinical transformation of a cryopreserved bone sample library and repair and regeneration of bone tissue defects.

In one aspect, the invention provides compounds of Formula I, and salts, hydrates and isomers thereof. In another aspect, the invention provides a method of promoting bone formation in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of Formula I. The present invention also provides orthopedic and periodontal devices, as well as methods for the treatment of renal disease, diabetes, bone loss, and cancer, using a compound of Formula I.

The invention belongs to the technical field of medicines, and particularly relates to application of lycium barbarum glycopeptide in preparation of a medicine for preventing or treating senile ossification. The experimental results show that the wolfberry glycopeptide can improve the posterior limb movement ability and the bone trabecula condition of old mice by increasing the femoral hardness, relieving the bone tissue calcium loss condition, improving the bone formation rate, promoting osteoblasts and inhibiting osteoclasts, so that the effect of treating bone aging is achieved. As a traditional Chinese medicinal material extraction product, the lycium barbarum glycopeptide can be effectively used for preventing and treating senile ossification, has the prospect of being developed into the medicine for preventing and treating senile ossification, provides more treatment choices for clinically preventing or treating senile ossification, and has important social benefits and economic values.

The invention relates to a device for bone formation, bone reshaping or healing of bone in dental, oral and maxillofacial applications, specifically in connection with installation of dental implants. The device comprises a sheet structure made of an inert material, wherein the sheet structure has an inner surface intended to be directed towards the bone and an outer surface intended to be directed away from the bone. The geometrical features of the cavity formed between the inner surface of the device and the initial bone surface when the device is installed at the intended location is further used to improve and plan the treatment. The device is customized by means of digital planning based on the initial and the optimal bone volume for the intended treatment. Modifications of the device can be introduced to facilitate a combined installation of dental implants with the device.

The present application belongs to the field of biomedicine, and relates to an inducer for inducing mesenchymal stem cells to differentiate into estradiol-secreting cells. The inducer for inducing mesenchymal stem cells to differentiate into estradiol-secreting cells is based on a human mesenchymal stem cell serum-free culture medium, and is composed of the following components in a mass concentration ratio: bone morphogenetic protein-4 20-60 mg / L, bone morphogenetic protein-7 20-60 mg / L, tretinoin 2-8 mg / L, resveratrol 2-8 mg / L, icariin 2-8 mg / L, benzamide 2-8 ug / L, chloroplatinic acid hexahydrate 2-8 ug / L, ethanolamine 2-8 ug / L, erythropoietin 2-10 ug / L, and vascular endothelial growth factor 2-10 ug / L. The inducer for inducing mesenchymal stem cells to differentiate into estradiol-secreting cells has high induction efficiency.

The present invention provides a method for producing neural crest cells from pluripotent stem cells, the method comprising: a step (1) of subjecting pluripotent stem cells to suspension culture in a culture medium containing an ALK inhibitor and a bone morphogenetic protein; and (2) performing suspension culture in a culture medium containing an ALK inhibitor and a GSK-3beta inhibitor.